US regulatory status: approved.
pharma · Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · IgA Nephropathy (IgAN) · VERA
Vera Therapeutics
Vera Therapeutics drug portfolio — 18 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
4539 Metropolitan Ct, Frederick, Maryland 21704, US HQ
2018 Founded
9 Employees
Public company Type
VERA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4539 Metropolitan Ct, Frederick, Maryland 21704, US
- Founded
- 2018
- Employees
- 9
- Programs
- 0
- Drugs
- 18
- Patents
- 7
Vera Therapeutics pipeline
Portfolio lens on 18 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Vera Therapeutics drug portfolio — 18 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor beta.
- Target
- Estrogen receptor beta
- Mechanism
- Estrogen receptor beta modulator
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Vera Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Vera Therapeutics's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Vera Therapeutics in public FDA and regional records. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
Development asset linked to Vera Therapeutics in public FDA and regional records. Molecular target: Focal adhesion kinase 1.
- Target
- Focal adhesion kinase 1
- Mechanism
- Focal adhesion kinase 1 inhibitor
-
US regulatory status: approved. Molecular target: Pyruvate dehydrogenase [NADP(+)].
- Target
- Pyruvate dehydrogenase [NADP(+)]
- Mechanism
- Pyruvate:ferredoxin oxidoreductase inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pandemic influenza vaccine (h5n1) (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Vera Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
peginterferon alfa-2a
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
pregabalin
Nervous system (N02)US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
Development asset linked to Vera Therapeutics in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I, mitochondrial inhibitor
-
trastuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
US regulatory status: approved.